Rigel Pharmaceuticals | RIGL - Чистый доход





Чистый доход Изменить Дата
Agenus USD -10.63M 74.49M 2025-12
Amgen USD 1.82B 486M 2026-03
Anika Therapeutics USD 292K 2.62M 2025-12
Arrowhead Research USD -132.73M 163.54M 2026-03
AstraZeneca USD 3.08B 754M 2026-03
BioMarin Pharmaceutical USD 105.53M 152.1M 2026-03
Bristol-Myers Squibb USD 2.68B 1.59B 2026-03
Celldex Therapeutics USD -78.68M 2.63M 2026-03
Daiichi Sankyo JPY 86.63B 41.32B 2025-12
Eli Lilly USD 7.4B 760M 2026-03
Halozyme Therapeutics USD 150.05M 291.64M 2026-03
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -93M 136M 2026-03
Karyopharm Therapeutics USD -102.2M 71.42M 2025-12
Ligand Pharmaceuticals USD -13.34M 58.13M 2026-03
MacroGenics USD -14.16M 30.98M 2025-12
Neurocrine Biosciences USD 197.9M 44.2M 2026-03
Pfizer USD 2.69B 4.34B 2026-03
Regeneron Pharmaceuticals USD 727.2M 117.4M 2026-03
Rigel Pharmaceuticals USD 12.42M 13.45M 2024-09
Sangamo BioSciences USD -36.13M 12.96M 2024-06
Ultragenyx Pharmaceutical USD -185M 56M 2026-03
Veracyte USD 28.71M 12.44M 2026-03